{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:34:34Z","timestamp":1793468074002,"version":"4.5.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Medical Faculty and University Hospital of the Eberhard Karls University","award":["681\/2011BO2; 647\/2016BO2"],"award-info":[{"award-number":["681\/2011BO2; 647\/2016BO2"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the effect of autologous stem cell transplantation (aSCT) on functional antibodies (abs) to the angiotensin II type-1-receptor (AT1R) and topoisomerase-I (topo-I) in SSc-patients and to analyse their prognostic relevance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Material and methods<\/jats:title>\n                  <jats:p>Forty-three SSc-patients in whom aSCT was performed were analysed. Thirty-one patients had a favourable outcome after aSCT (group 1), 12 patients showed no response or relapse (group 2). Patients\u2019 sera were tested for anti-AT1R and anti-topo-I antibodies by ELISA and in a luminometric assay (LA) using AT1R-expressing Huh7-cells for inhibitory or stimulatory anti-AT1R antibodies before and after aSCT (4\u2013217\u2009months, median 28\u2009months). Anti-topo-I antibodies were also analysed for their capacity to inhibit enzyme function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 70% of the SSc patients had anti-topo-I- and 51% anti-AT1R antibodies in the ELISA before aSCT. In all instances, anti-topo-I antibodies inhibited topo-I-enzyme function. In the LA, 40% had stimulatory and 12% inhibitory anti-AT1R antibodies. Anti-topo-I- and anti-AT1R-reactivity (ELISA) significantly decreased after aSCT. Before aSCT, anti-topo-I-reactivity was significantly higher in group 2 patients than in group 1 patients (P\u2009&amp;lt;\u20090.001), while there was no difference between both groups for anti-AT1R antibodies detected by ELISA. Stimulatory anti-AT1R antibodies detected by LA were confined to group 1-patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Reactivity of functionally active anti-AT1R antibodies was not influenced by aSCT, while anti-topo-I antibodies decreased after aSCT. The fact that anti-topo-I antibodies inhibited enzyme function in all instances supports the hypothesis of a pathogenetic role of the topo-I antigen\/antibody-system in SSc. High anti-topo-I reactivity before aSCT was associated with an unfavourable, presence of stimulatory anti-AT1R antibodies with a favourable course after aSCT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac549","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T18:19:31Z","timestamp":1665598771000},"page":"2168-2177","source":"Crossref","is-referenced-by-count":12,"title":["Functional autoantibodies in systemic sclerosis: influence of autologous stem cell transplantation and correlation with clinical outcome"],"prefix":"10.1093","volume":"62","author":[{"given":"Lukas","family":"Bankamp","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, University of T\u00fcbingen , T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Preu\u00df","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University of T\u00fcbingen , T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0201-0686","authenticated-orcid":false,"given":"Ann-Christin","family":"Pecher","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University of T\u00fcbingen , T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichard","family":"Vogel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University of T\u00fcbingen , T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-3195","authenticated-orcid":false,"given":"J\u00f6rg","family":"Henes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University of T\u00fcbingen , T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6111-3901","authenticated-orcid":false,"given":"Reinhild","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University of T\u00fcbingen , T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"2023060113234047900_keac549-B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.55563\/clinexprheumatol\/izadb8","article-title":"One year in review 2021: systemic sclerosis","volume":"39(Suppl 131","author":"Di Battista","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2023060113234047900_keac549-B2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11926-014-0473-0","article-title":"Role of cellular senescence and NOX4-mediated oxidative stress in systemic sclerosis pathogenesis","volume":"17","author":"Piera-Velazquez","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"2023060113234047900_keac549-B3","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3390\/ijms21093069","article-title":"Pathogenic roles of autoantibodies and aberrant epigenetic regulation of immune and connective tissue cells in the tissue fibrosis of patients with systemic sclerosis","volume":"21","author":"Tsai","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2023060113234047900_keac549-B4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/cei.13426","article-title":"Toll-like receptors in mediating pathogenesis in systemic sclerosis","volume":"201","author":"Frasca","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"2023060113234047900_keac549-B5","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.3390\/ijms21144985","article-title":"Role of alarmins in the pathogenesis of systemic sclerosis","volume":"21","author":"Giovannetti","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2023060113234047900_keac549-B6","doi-asserted-by":"crossref","first-page":"10514","DOI":"10.1016\/S0021-9258(19)86738-8","article-title":"Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma","volume":"254","author":"Douvas","year":"1979","journal-title":"J Biol Chem"},{"key":"2023060113234047900_keac549-B7","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"New Engl J Med"},{"key":"2023060113234047900_keac549-B8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/art.1780310207","article-title":"Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis","volume":"31","author":"Steen","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2023060113234047900_keac549-B9","first-page":"98","article-title":"Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis","volume":"35(Suppl 106)","author":"Iniesta Arandia","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2023060113234047900_keac549-B10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0014-5793(86)81117-6","article-title":"Inhibition of topoisomerase I by antibodies in sera from scleroderma patients","volume":"209","author":"Samuels","year":"1986","journal-title":"FEBS Lett"},{"key":"2023060113234047900_keac549-B11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13075-019-1931-x","article-title":"Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional?","volume":"21","author":"Corallo","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023060113234047900_keac549-B12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.humimm.2019.04.012","article-title":"Antibodies against Angiotensin II Type 1 and Endothelin A Receptors: relevance and pathogenicity","volume":"80","author":"Philogene","year":"2019","journal-title":"Hum Immunol"},{"key":"2023060113234047900_keac549-B13","doi-asserted-by":"crossref","first-page":"564526","DOI":"10.3389\/fimmu.2020.564526","article-title":"What makes antibodies against g protein-coupled receptors so special? A novel concept to understand chronic diseases","volume":"11","author":"Riemekasten","year":"2020","journal-title":"Front Immunol"},{"key":"2023060113234047900_keac549-B14","doi-asserted-by":"crossref","first-page":"786039","DOI":"10.3389\/fimmu.2021.786039","article-title":"Functionally active antibodies to the angiotensin II Type 1-receptor measured by a luminometric bioassay do not correlate with clinical manifestations in systemic sclerosis: a comparison with antibodies to vascular receptors and topoisomerase I detected by ELISA","volume":"12","author":"Bankamp","year":"2021","journal-title":"Front Immunol"},{"key":"2023060113234047900_keac549-B15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1056\/NEJMoa035717","article-title":"Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection","volume":"352","author":"Dragun","year":"2005","journal-title":"New Engl J Med"},{"key":"2023060113234047900_keac549-B16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.2010.135772","article-title":"Involvement of functional autoantibodies against vascular receptors in systemic sclerosis","volume":"70","author":"Riemekasten","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023060113234047900_keac549-B17","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023060113234047900_keac549-B18","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar4503","article-title":"Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients","volume":"16","author":"Gunther","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2023060113234047900_keac549-B19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023060113234047900_keac549-B20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3899\/jrheum.110868","article-title":"Optimization of autologous stem cell transplantation for systemic sclerosis \u2013 a single-center longterm experience in 26 patients with severe organ manifestations","volume":"39","author":"Henes","year":"2012","journal-title":"J Rheumatol"},{"key":"2023060113234047900_keac549-B21","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrrheum.2011.136","article-title":"Stem cells: HSCT for systemic sclerosis\u2013swallows and summers","volume":"7","author":"Tyndall","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2023060113234047900_keac549-B22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party","volume":"106","author":"Henes","year":"2021","journal-title":"Haematologica"},{"key":"2023060113234047900_keac549-B23","first-page":"53","article-title":"Resetting the immune system with immunoablation and autologous haematopoietic stem cell transplantation in autoimmune diseases","volume":"34","author":"Alexander","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2023060113234047900_keac549-B24","first-page":"451","article-title":"Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation","volume":"56","author":"Henes","year":"2017","journal-title":"Rheumatology"},{"key":"2023060113234047900_keac549-B25","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023060113234047900_keac549-B26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/cei.12324","article-title":"A novel luminescence-based method for the detection of functionally active antibodies to muscarinic acetylcholine receptors of the M3 type (mAchR3) in patients' sera","volume":"177","author":"Preuss","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2023060113234047900_keac549-B27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0076-6879(83)00050-6","article-title":"Multiple forms of rat liver type I topoisomerase","volume":"100","author":"Martin","year":"1983","journal-title":"Methods Enzymol"},{"key":"2023060113234047900_keac549-B28","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1136\/annrheumdis-2021-222088","article-title":"Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching","volume":"81","author":"Yue","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023060113234047900_keac549-B29","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.bbmt.2020.07.029","article-title":"AT1R activating autoantibodies in hematopoietic stem cell transplantation","volume":"26","author":"Bradford","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023060113234047900_keac549-B30","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/art.10098","article-title":"Topotecan and the development of scleroderma or a scleroderma-like illness","volume":"46","author":"Ene-Stroescu","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2023060113234047900_keac549-B31","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.33377","article-title":"The autoantigen DNA topoisomerase I interacts with chemokine receptor 7 and exerts cytokine-like effects on dermal fibroblasts","volume":"64","author":"Arcand","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2023060113234047900_keac549-B32","doi-asserted-by":"crossref","first-page":"100140","DOI":"10.1016\/j.xcrm.2020.100140","article-title":"Osteopontin links myeloid activation and disease progression in systemic sclerosis","volume":"1","author":"Gao","year":"2020","journal-title":"Cell Rep Med"},{"key":"2023060113234047900_keac549-B33","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.21646","article-title":"DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients","volume":"54","author":"Henault","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023060113234047900_keac549-B34","doi-asserted-by":"crossref","first-page":"R128","DOI":"10.1186\/ar3435","article-title":"Decreased catalytic function with altered sumoylation of DNA topoisomerase I in the nuclei of scleroderma fibroblasts","volume":"13","author":"Zhou","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2023060113234047900_keac549-B35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes","volume":"54","author":"Matsushita","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023060113234047900_keac549-B36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/art.41927","article-title":"Defective early B cell tolerance checkpoints in patients with systemic sclerosis allow the production of self antigen-specific clones","volume":"74","author":"Glauzy","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023060113234047900_keac549-B37","doi-asserted-by":"crossref","first-page":"6138","DOI":"10.4049\/jimmunol.164.12.6138","article-title":"Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive T cells","volume":"164","author":"Kuwana","year":"2000","journal-title":"Journal of immunology"},{"key":"2023060113234047900_keac549-B38","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/art.40016","article-title":"Scleroderma peripheral B lymphocytes secrete interleukin-6 and transforming growth factor beta and activate fibroblasts","volume":"69","author":"Dumoitier","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023060113234047900_keac549-B39","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clim.2017.05.013","article-title":"Increased proportions of functionally impaired regulatory T cell subsets in systemic sclerosis","volume":"184","author":"Ugor","year":"2017","journal-title":"Clin Immunol"},{"key":"2023060113234047900_keac549-B40","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2016-210189","article-title":"Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages","volume":"76","author":"Maier","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023060113234047900_keac549-B41","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1002\/art.30539","article-title":"Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling","volume":"63","author":"Yoshizaki","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2023060113234047900_keac549-B42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13075-019-1889-8","article-title":"Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern","volume":"21","author":"Gernert","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023060113234047900_keac549-B43","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2023060113234047900_keac549-B44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaut.2012.05.010","article-title":"Bone marrow of NZB\/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunity","volume":"39","author":"Mumtaz","year":"2012","journal-title":"J Autoimmun"},{"key":"2023060113234047900_keac549-B45","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1210\/clinem\/dgz292","article-title":"Prospective trial of functional thyrotropin receptor antibodies in graves disease","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2023060113234047900_keac549-B46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2741\/4707","article-title":"Loss of balance in normal GPCR-mediated cell trafficking","volume":"24","author":"Cabral-Marques","year":"2019","journal-title":"Front Biosci"},{"key":"2023060113234047900_keac549-B47","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1210\/jc.2013-3282","article-title":"Autoimmune mechanisms activating the angiotensin AT1 receptor in \u2018primary\u2019 aldosteronism","volume":"99","author":"Kem","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac549\/46560337\/keac549.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/6\/2168\/50500705\/keac549.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/6\/2168\/50500705\/keac549.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T13:32:09Z","timestamp":1685626329000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/6\/2168\/6759365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,10,12]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac549","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2022,10,12]]}}}